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Vascular ulcers are a serious complication of peripheral vascular disease, especially in diabetics. Several approaches to treat the
wounds are proposed but they show poor outcomes and require long healing times. Hepatocyte Growth Factor/Scatter Factor
(HGF/SF) is a pleiotropic cytokine exertingmany biological activities through the c-Met receptor.This study was aimed at verifying
whether HGF/SF influences proliferation, migration, and angiogenesis on mesenchymal stem cells isolated from human arteries
(hVW-MSCs). hVW-MSCswere exposed toNIBSCHGF/SF (2.5, 5, 10, and 70 ng/mL) from6 hrs to 7 days.HGF and c-METmRNA
and protein expression, cell proliferation (Alamar Blue andKi–67 assay), migration (scratch and transwell assays), and angiogenesis
(Matrigel) were investigated. hVW-MSCs displayed stemness features and expressed HGF and c-MET. HGF/SF did not increase
hVW-MSC proliferation, whereas it enhanced the cell migration, the formation of capillary-like structures, and the expression of
angiogenic markers (vWF, CD31, and KDR). The HGF/SF effects on hVW-MSC migration and angiogenic potential are of great
interest to acceleratewoundhealing process. Local delivery ofHGF/SF could therefore improve the healing of unresponsive vascular
ulcers.
1. Introduction
The lower limb ulceration has prevalence of about 3% in the
adult population over 65 years [1]. Foot ulcers mainly affect
the arterial system and are particularly severe and devastating
among diabetic patients, where they tend to become chronic.
For this reason, foot ulcers significantly affect the expectancy
and quality life of such patients, as well as healthcare
expenditures. Arterial ulcers are a consequence of diffuse
atherosclerotic narrowing of the leg arteries resulting in a
significant reduction of blood flow to the lower limb. The
main therapy consists of restoring blood flow by angioplasty
or bypass and the removal of the debridement and the
necrotic tissue to accelerate the wound healing. Additional
treatments have been recently introduced, such as biological
dressing, physical therapy (hyperbaric oxygen and negative
pressure therapy), and compression therapy [2]; however,
clinical results are still less than optimal.
To date, surgical revascularization remains the mile-
stone of any arterial ulcer treatment; however, blood flow
restoration should be associated with treatments aimed at
reactivating ineffective autologous healing processes, such as
inflammatory cell responses and local angiogenesis whose
ineffectiveness is responsible for incomplete and delayed
wound healing. In this respect, the use of gene and cell
therapies [3] and natural or synthetic engineered matrices
[2, 4] has gained interest in the scientific community; as
an example, interesting results on the complete wound
healing were seen after transplantation of biomimetic tissue
engineered dermis substitutes with allogeneic keratinocytes
and fibroblasts cells inside ulcerated tissue [5, 6].
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Interestingly, both animal and human studies advocate
the adult mesenchymal stem cells derived from bonemarrow
[7, 8] as well as adipose tissue [9–11] as ideal candidates to
treat nonhealing wound due to their ability to differentiate in
multiple mesengenic lineages and their capability to facilitate
angiogenesis through the secretion of proangiogenic growth
factors, even if their exact contribution to wound healing has
not been completely understood.
Human derived autologous platelet-rich plasma (PRP)
is also a promising wound healing treatment, due to the
mitogenic and chemoattracting effects exerted by growth fac-
tors released at high concentrations after platelet 𝛼-granules
degranulation [12]. Some case reports and few clinical trials
[13–15] showed positive effects of PRP on reepithelialization
of nonhealing wounds.
Alternatively, single or combined growth factors
including Platelet-Derived Growth Factor (PDGF), Vascular
Endothelial Growth Factor (VEGF), Transforming Growth
Factor-beta (TGB-beta), Fibroblast Growth Factor (FGF),
Epidermal Growth Factor (EGF), and Granulocyte Ma-
crophage-Colony Stimulating Factor (GM-CSF) are largely
studied [16, 17], thanks to their multiple effects on wound
healing including cell proliferation and mobilization,
extracellular matrix production, and angiogenesis even
though different outcomes are reported. In addition, the
Hepatocyte Growth Factor/Scatter Factor (HGF/SF) is a
multifunctional cytokine involved in numerous biological
responses including cell proliferation/survival, angiogenesis,
morphogenesis, andmotogenesis [18] aswell as inflammation
and fibrosis inhibition [19]; these actions are exerted through
its tyrosine kinase receptor, c-Met [20], that is primarily
expressed in epithelial cells; however, few reports indicate
that adult mesenchymal stem cells also express c-Met
[21–23].
In this study, we tested the in vitro effects of HGF/SF on
a multipotent mesenchymal stem cells population that our
research group isolated from the vascular wall of adult human
arteries (hVW-MSCs) [24]. The hVW-MSC exposure to
HGF/SF could represent a strategy to improve and accelerate
the wound healing process in foot ulcers. In particular,
we investigated the HGF/SF effect on cell proliferation and
viability using Alamar Blue assay and Ki-67 immunofluores-
cence staining, cell migration and motility abilities through
scratch and transwell assays, and angiogenic potential to form
capillary-like structures in a Matrigel assay.
2. Materials and Methods
2.1. Human Vascular Wall-Mesenchymal Stem Cell Isolation
and Culture Condition. Vascular wall-mesenchymal stem
cells (hVW-MSCs) isolated from human arteries were used
according to the ethic protocol (APP-13-01) approved by the
Local Ethics Committee of University Hospital St. Orsola-
Malpighi of Bologna in Italy and with consent informed.
Their isolation, characterization, and stemness investigation
were performed using methods described elsewhere [24].
Briefly, the human arteries were enzymatically digested
overnight at 37∘C in a rotor apparatus using serum-free
DMEM culture medium supplemented with 0.3mg/mL
Liberase type II (Roche, Milan, Italy) followed by filtration
through 40–70–100𝜇m nylon mesh cell strainer (Becton
Dickinson; Franklin Lakes, NJ) seeded on collagen-coated
flasks and cultured in completeDMEMplus 20%Fetal Bovine
Serum (FBS) at 37∘C in a humidified atmosphere of 5% CO
2
for 3 days. After floating cells removal, adherent hVW-MSCs
were expanded until confluence replacing the cell culture
with freshmedium every 2-3 days. Immunophenotype, stem-
ness features, and multilineage potential were investigated
confirming their mesenchymal identity [24]. In this study,
experiments were performed using cells taken at passages 3
and 4 and cultured inDMEMplus 10%of FBSwith orwithout
Hepatocyte Growth Factor/Scatter Factor (HGF/SF) (WHO
Reference Reagent, HGF/SF, NIBSC code: 96/564, National
Institute for Biological Standards and Control, Potter Bar,
Hertfordshire, ENG 3QG) at different time (from 6 hrs to
7 days) and concentrations (from 2.5 to 70 ng/mL). Cell
starvation with low percentage of serum (0.5% FBS) for 12 hrs
was performed to induce cell cycle synchronization before
pretreatment with 0.2 𝜇MPHA-665752 inhibitor (Tocris Bio-
science, Bristol, UK) for 12 hrs, followed byHGF/SF addition.
All experiments were executed in triplicate.
2.2. RNA Extraction and RT-PCR. RT-PCR was performed
on hVW-MSCs to detect the basal expression of HGF and its
receptor c-Met. Total RNA was extracted from hVW-MSCs
using TRIreagent according to the manufacturer’s instruc-
tions (TRIzol reagent; Invitrogen). Reverse transcription of
1 𝜇g of total RNA was carried out in a 20𝜇L volume of
reaction using a High Capacity Reverse Transcription Kit
(Applied Biosystems, Carlsbad, CA,USA). Polymerase Chain
Reaction (PCR) products were analyzed by electrophoresis
on a 2% agarose gel, stained with ethidium bromide and
photographed under ultraviolet light. All PCR product sizes
were identified loading a 100-base-pair (bp) DNA ladder
and normalized to GAPDH, used as housekeeping gene. The
PCRprimerswere purchased fromSigma-Aldrich.Genes and
respective primers are presented in Table 1.
2.3. Western Blot Analysis. Total cellular proteins were
extracted by untreated and treated hVW-MSCs using lysis
buffer (KH2PO4 0.1M pH 7.5, NP-40 1%, and 0.1mM 𝛼-
glycerolphosphate, added with complete protease inhibitors
cocktail, Roche Diagnostics) and quantified spectrophomet-
ricallywith the Bio-RadProteinAssay (Bio-RadLaboratories,
Hempstead, UK). Thirty 𝜇g proteins were subjected to 8%
SDS-PAGE and transferred to nitrocellulose membrane (GE
Healthcare Life Sciences, Amersham) at 30mA for 2 hrs and
30 minutes. The membrane was blocked with 5% nonfat dry
milk in TBS-tween for 1 hour at room temperature (RT),
incubated with primary antibodies against c-Met (1 : 500,
Santa Cruz Biotechnologies), HGF (1 : 500, Santa Cruz
Biotechnologies), and anti-𝛼-actin (clone AC-74, Sigma-
Aldrich) at 4∘C overnight. Secondary antibodies (human
anti-rabbit/mouse horseradish peroxidase-conjugated (GE
Healthcare, Milan, Italy)) were used at 1 : 10000 dilutions for
1 h at room temperature (RT). Protein signal was detected
using Westar 𝜂C chemiluminescent substrate (Cyanagen).
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Table 1: List of primers used for RT-PCR in hVW-MSCs.
Gene Primer sequence Product size (bp) 𝑇 (∘C)
GAPDH FWD 5
󸀠-ACCACAGTCCATGCCATCAC-3󸀠 452 61
REV 5󸀠-TCCACCACCCTGTTGCTGTA-3󸀠
c-MET FWD 5
󸀠-AGAAATTCATCAGGCTGTGAAGCGCG-3󸀠 440 68
REV 5󸀠-TTCCTCCGATCGCACACATTTGTCG-3󸀠
HGF FWD 5
󸀠-TTTGCCTTCGAGCTATCGGG-3󸀠 254 62
REV 5󸀠-GCAAGAATTTGTGCCGGTGT-3󸀠
2.4. Cell Viability and Proliferation Evaluation. Cell viabil-
ity was investigated using Alamar Blue fluorescence assay
(Invitrogen, Milan, Italy). The hVW-MSCs were seeded in
a 12-multiwell plate at the density of 3 × 104 and cultured
in complete DMEM with or without HGF/SF (2.5, 5, and
10 ng/mL) for 1, 3, and 7 days. Alamar Blue solution (10%
v/v in cultured medium) was added to each well at the
end of treatments and incubated for 4 hrs at 37∘C according
to the manufacturer’s instruction. Alamar Blue fluorescence
(Ex/Em = 540/590 nm) of three replicates in each well was
measured in a Wallac VICTOR2 multiplate reader (Perkin
Elmer, Milan, Italy). In addition, a standard polystyrene
well was used to measure the background fluorescence;
this fluorescence was subtracted from the reading of each
well.
Cell proliferation was assessed using single immunoflu-
orescence staining for cycling cells expressing Ki-67 protein.
hVW-MSCs were plated at a density of 6 × 105 on coverslip in
6-well plates in DMEMovernight to allow the cell confluence
and treatedwith orwithoutHGF/SF (2.5, 5, 10, and 70 ng/mL)
for 6 and 24 hrs. In parallel experiments, additional cell-
seeded glass was starved in 0.5% FBS for 12 hrs, pretreated
with 0.2𝜇MPHA-665752 inhibitor, and subjected to HGF/SF
exposure at the same time and concentrations.Untreated cells
were used as a control.
2.5. Immunofluorescence Staining. At the end of treat-
ments, cells were washed, fixed, and permeabilized in 2%
paraformaldehyde in PBSwith 1%TrytonX-100 for 4minutes
at RT, blocked with 1% bovine serum albumin (BSA) for 30
minutes at RT to reduce nonspecific staining, and labeled
with monoclonal antibody against nuclear transcription fac-
tor Ki-67 (1 : 100, Novocastra, Leica Microsystems, Wetzlar,
Germany) and intermediate filament Vimentin (1 : 100, Dako
Cytomation, Glostrup, Denmark). Samples were washed,
stained with AlexaFluor-488 (1 : 250, Life Technology, Carls-
bad, CA, USA) secondary antibody in the dark, and counter-
stainedwith Pro Long antifade reagent withDAPI (Molecular
Probes, Milan, Italy). All incubations were performed for 1 hr
at 37∘C in a wet chamber; both antibodies were diluted in
1% BSA in PBS. Samples were observed and photographed
in a Leica DMI6000 B inverted fluorescence microscope
(Leica Micro-systems, Wetzlar, Germany). Negative control
was performed by omitting the primary antibody and no
fluorescence was detected. For each experimental condition,
the number of Ki-67 intensely stained cells as well as DAPI
stained nuclei was manually counted on ten random fields
and their valueswere expressed in percentage as ratio of Ki-67
stained cells on total cells number.
2.6. In Vitro Wound Healing Assay. Cell migration was
investigated using a scratch assay. HVW-MSCs were seeded
in 12-multiwell plate at a density of 1 × 105/well and grown
until to confluence. Cell monolayers were wounded with a
p200 pipette tip, washed with PBS to remove cell debris, and
treated with complete DMEM containing HGF/SF (2.5, 5, 10,
and 70 ng/mL) for 24 hrs. In further experiments, cells were
starved, inhibited with 0.2 𝜇M PHA-665752, and cultured in
presence of HGF/SF at the same time and concentrations.
At the end of HGF/SF treatment for both experiments, cells
were fixed in absolute methanol for 10 minutes, washed in
PBS, stained with 0.1% Crystal Violet in 25% methanol for
30 minutes, and air-dried; all steps were performed at RT.
Thewound closure was observed under a phase-contrast light
microscope (LM) equipped with a digital camera (Nikon),
acquiring images for each sample at time 0 and 24 hrs, respec-
tively, using Software NIS-elements D3.2 Nikon (Tokyo,
Japan). Computer-assisted image analysis (Image-Pro Plus
software,Media Cybernetics, http://www.mediacy.com/) was
employed to perform the quantification of the area of cells
migrated into scratched area as well as the total wounded
area in three different fields. Values were expressed in
percentage as ratio of migrated cell area on total scratched
area. Additional cell-seeded glasses were used for Vimentin
intermediate filaments immunofluorescence staining.
2.7. Transwell Migration Assay. The cellular ability to migrate
through a porous membrane under the influence of a
chemoattractant factor was evaluated using transwell cham-
bers (Costar, Corning Incorporated, NY, USA). Briefly,
500𝜇L ofDMEMwith 10%FBSwith orwithout chemoattrac-
tant HGF/SF (10 ng/mL) was placed below the polycarbonate
membrane with 8 𝜇m pores while 300 𝜇L of cellular suspen-
sion containing 2.5 × 104 hVW-MSCs in growthmediumwas
plated on the upper layer of the membrane for 24 hrs at 37∘C
in incubator. After the manual removal of the nonmigrated
cells from the upper side of the membranes, the inserts
were detached from the plastic support using a scalpel, fixed,
stained with 0.1% Crystal Violet for 30 minutes at RT, and
mounted on glass slide. The cells migrated in the lower layer
were observed using a Leitz Diaplan LM (Wetzlar, Germany)
equipped with a video camera (JVC 3CCD video camera,
KY-F55B, Jokohama, Japan). Digital images were acquired
at 10x of magnification using Image-Pro Plus 6 software
(Media Cybernetics). Additional membranes were processed
for SEM analysis.
2.8. Scanning Electron Microscopy (SEM). For SEM, sam-
ples were rinsed in 0.15M phosphate buffer to remove
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the culture medium, fixed in 2.5% buffered glutaraldehyde
(TAAB Laboratories, UK) overnight at 4∘C, washed again
in phosphate buffer, postfixed in 1% osmium tetroxide in
0.1M phosphate buffer, wet in distilled water, and dehydrated
with increasing ethanol concentrations (70–100%). Each
step was performed at RT for 15 minutes. For drying the
samples, they were immersed before in a solution of 50%
absolute ethanol/50% hexamethyldisilazane (HMDS, Fluka
Analytical, Sigma, Steinheim, Germany) and after in pure
HMDS for 30 minutes each passage at RT and finally air-
dried. Before observation, the samples were mounted on
aluminum supports (Multilab type stub pin 1/2, Surrey, UK)
using a silver paste maintaining the cell-seeding surface,
coated with gold in a sputtering device (Quorum Q150RS,
Technologies Ltd., Laughton, UK), and observed at 5–10 kV
with a Quanta 250 (FEI Company, Milan, Italy) scanning
electron microscope.
2.9. In Vitro Tube Formation Assay. Angiogenic potential to
form capillary-like tubes was measured using a semisolid
matrix after culturing confluent hVW-MSCs for 7 days
in DMEM containing 2% FBS with 10 ng/mL HGF/SF or
50 ng/mL VEGF (Sigma); control cells were maintained in
basal medium plus 10% FBS. At the end of treatments, a
96-well culture plate was coated with 50𝜇L of Matrigel (BD
Bioscence) solution for 1 hr at 37∘C. After that, untreated
and treated cell suspensions were placed onto the solidified
layer of Matrigel at the density of 15 × 103 hVW-MSCs for
well. Human Umbilical Vein Endothelial Cells (HUVEC)
were used as a positive control. Tubular blood vessels-like
structures were observed under inverted LM and docu-
mented with a digital camera (Nikon) after 2, 6, and 24 hrs.
To quantify in vitro angiogenesis, the number of capillary-
like structures was manually counted on digitalized images
taken at 4xmagnification for each experimental condition. In
parallel experiments, flow cytometrywas performed to detect
the expression of vWF, KDR, and CD31 mature endothelial
cell markers in control as well as growth factors-treated
cells. For surface antigen, the treated cells were rinsed in
PBS, labeled with primary antibodies against KDR-APC and
CD31-PE. To reveal vWF expression, the cells were fixed
and permeabilized with the IntraPep Kit (Beckman-Coulter),
incubated with von Willebrand Factor (vWF; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), and subsequently
incubated with anti-mouse IgG-FITC (Dako) secondary
antibody. The endothelial lineage commitment was quanti-
fied in all experimental conditions attributing a score from
0 to 4 according to the flow cytometry values of each
mature endothelial cell marker. Final values are reported as
mean.
2.10. Statistical Analysis. Results were expressed as themeans
± SEM. GraphPad Prism 5.0 software (GraphPad Prism soft-
ware, San Diego, CA) was used to perform statistical analysis
and to create graphical representations. Statistical differences
between samples were determinated using unpaired Student’s
t-test and one-way ANOVA test for comparison between
more than two groups, followed by Bonferroni posttest; 𝑝
value < 0.05 was considered to be statistically significant.
3. Results
3.1. hVW-MSC Isolation and Stemness Property. hVW-MSCs
isolated from human arteries showed a spindle-shaped mor-
phology and a marked adhesion growth (Figure 1(a)). hVW-
MSCs expressed mesenchymal (CD44, CD73, CD90, CD105,
HLA-G), stemness (Stro-1, Oct-4, and Notch-1), pericyte
(CD146, PDGFR-𝛽, and NG2), and neuronal (nestin) mark-
ers (Figure 1(b)), together with the plasticity to differen-
tiate in multiple mesengenic lineages, clonogenicity, and
immunomodulatory functions; details on their morphology,
immunophenotype, and molecular and functional features
are reported elsewhere [24].
3.2. HGF and c-MET mRNA and Protein Expression in hVW-
MSCs. In a previous study, Neuss et al. demonstrated that
hMSCs derived from bone marrow expressed HGF and its
receptor, c-Met [21]. In this study we verified whether hVW-
MSCs, recovered from human arteries, also may constitu-
tively possess these genes. Gene expression analysis showed
that hVW-MSCs express HGF and c-MET receptor mRNA
(Figure 1(c)). Western Blot confirmed the expression of
the c-Met receptor in hVW-MSCs and showed increased
protein levels in hVW-MSCs exposed to HGF/SF, especially
at 10 ng/mL (24 hrs). Meanwhile, the expression of the HGF
protein did not show evident differences under HGF/SF
stimulation (Figure 1(d)).
3.3. HGF/SF Effect on hVW-MSC Proliferation. hVW-MSCs
were exposed to 2.5, 5, and 10 ng/mL of HGF/SF for a wide
range of time (from 6 hrs to 7 days). From day 1 to day 3,
Alamar Blue fluorescence assay revealed an increased cell
viability in all experimental conditions including control that
was related to overall cell population doubling; no difference
between untreated and HGF/SF-treated hVW-MSCs was
seen at day 3 and day 7 (Figure 2(a)). The cell proliferation
following 6 hrs and 24 hrs of exposure to 2.5, 5, 10, and
70 ng/mL HGF/SF was assayed by Ki-67 staining. Immunos-
taining analysis on hVW-MSCs exposed to HGF/SF for 6 hrs
showed an increased Ki-67 expression in a dose-dependent
manner, in comparison to the untreated hVW-MSCs; the
percentage of Ki-67 positive cells was significantly higher
when hVW-MSCs were exposed to HGF/SF at 10 ng/mL
(29.6 ± 4.1 in HGF/SF-treated hVW-MSCs versus 19.4 ±
4.8 in untreated controls, 𝑝 < 0.05, one-way ANOVA test
followed by Bonferroni posttest). Conversely, after 24 hrs
of incubation, the percentage of cycling cells positive to
Ki-67 was significantly decreased in all the concentrations
tested (30.3 ± 5.6 in 2.5 ng/mL, 28.4 ± 1.5 in 5 ng/mL,
28.4 ± 4.3 in 10 ng/mL, and 26.5 ± 4.5 in 70 ng/mL, versus
39.9 ± 4.0 in control cells; 𝑝 < 0.05; one-way ANOVA
test followed by Bonferroni posttest) (Figure 2(b)). hVW-
MSCs exposed to PHA-665752 inhibitor showed a significant
decrease of Ki-67 expression levels (12.7 ± 5.9 versus 39.9 ±
4.0 unexposed hVW-MSCs, 𝑝 < 0.05, one-way ANOVA
test followed by Bonferroni posttest). The HGF/SF addition
to PHA-665752-pretreated hVW-MSCs restored the hVW-
MSCs proliferation and the percentage of Ki-67 positive cells
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Figure 1: hVW-MSC aspect and HGF/c-MET expression. (a) hVW-MSCs were enzymatically isolated from human arteries and, at passage 3,
they exhibited adherence to the plastic substrate and a typical spindle-shaped morphology. Scale bars = 100 𝜇m. (b) Flow cytometry analysis
of mesenchymal, stemness, pericyte, and hematopoietic and vascular markers expressed in our cell model of hVW-MSCs. Values are reported
in percentage of positivity. (c) Basal expression of HGF (252 bp) and c-MET (440 bp) mRNA in hVW-MSCs, detected by RT-PCR. (d) c-Met
and HGF protein detection on cell lysates of hVW-MSCs exposed to HGF/SF (0, 2.5, 5, and 10 ng/mL) for 24 hrs.
revealed overlapping results with those obtained without
PHA-665752 (Figure 2(c)). Results with c-Met inhibition
definitively confirmed that HGF/SF does not increase the
hVW-MSCs proliferation.
3.4. HGF/SF Effect on hVW-MSC Migration. To investigate
the in vitro HGF/SF effect on cell migration, we used a
wounded confluent hVW-MSC monolayer model cultured
with or without HGF/SF for 24 hrs. hVW-MSCs exposed
to HGF/SF (2.5, 5, 10, and 70 ng/mL) covered the wounded
area more efficiently than untreated controls. The cell migra-
tion was reduced by adding 0.2 𝜇M of the c-Met inhibitor,
PHA-665752, in the culture medium before any HGF/SF
treatment. Moreover, in absence of HGF/SF stimuli, hVW-
MSCs exhibited a spontaneous capacity to move into the
cell-free wounded area; the spontaneous migration was
probably stimulated by an autocrine mechanism related
to endogenous HGF release. The addition of HGF/SF to
PHA-pretreated hVW-MSCs did not completely restore the
cell migration (Figures 3(a) and 3(b)). To corroborate light
microscopy results, SEM investigation was performed at
the same doses and time of HGF/SF treatment. SEM con-
firmed the high efficacy of HGF/SF to promote hVW-MSC
migration into scratched area restoring the cell monolayer
scratched by p200 pipette tip when compared to control
cells (data not show); similar results were seen using single
immunofluorescence staining for Vimentin. Notably, while
Vimentin was expressed in all hVW-MSCs, the labeling
fluorescence intensity was more intense in the cells migrated
in the wound area; this fluorescence pattern was interpreted
as a feature of cytoskeleton remodeling (Figure 3(c)).
3.5. HGF/SF Effect on hVW-MSC Motility. The HGF/SF
ability to mobilize and chemoattract hVW-MSCs was tested
through a transwell migration assay. Crystal Violet dye
showed thatHGF/SF (10 ng/mL) enhancedhWV-MSCmotil-
ity when compared to spontaneous hVW-MSC migration.
At SEM, the majority of hVW-MSCs remained on the
seeding surface in absence ofHGF/SF; on the contrary, hVW-
MSCs efficiently colonized themigration surface after adding
10 ng/mL of HGF/SF to the lower compartment (Figures 4(a)
and 4(b)).
3.6. HGF/SF Effect on hVW-MSC Angiogenic Potential. The
hVW-MSC angiogenic differentiation under the presence
of HGF/SF was assessed in a 3D semisolid matrix assay.
HGF/SF (10 ng/mL) or VEGF (50 ng/mL) induced the for-
mation of capillary-like structures that peaked at 6 hrs and
persisted until 24 hrs. After 2 hrs of exposure to HGF/SF
or VEGF, hVW-MSCs aligned and branched from the cell
periphery to form tube-like structures. At 6 hrs, the density
of the HGF/SF or VEGF-induced capillary-like network
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Figure 2: Proliferative effect of HGF/SF on hVW-MSCs. (a) In vitro proliferation of hVW-MSCs exposed to HGF/SF assessed by Alamar
Blue fluorescence assay up to 7 days. From day 1 to day 3, the fluorescence intensity was increased in HGF/SF-treated hVW-MSCs including
untreated cells (red) while no difference was seen between hVW-MSCs stimulated by HGF/SF and untreated cells at 3 and 7 days. (b)
Representative images of cycling cells expressing Ki-67 protein after 6 and 24 hrs of incubation with HGF/SF, compared to controls (hVW-
MSCs). Ki-67 positive cells (green) and DAPI (nuclei in blue). After 6 hrs, the HGF/SF stimulation induced a slight increase of Ki-67 positive
hVW-MSCs percentage on total DAPI cells; after 24 hrs ofHGF/SF exposure, the percentage of Ki-67 positive cells is approximately reduced of
the 15% in all the experimental conditions. Scale bars = 50𝜇m. (c) Images and quantitative analysis of hVW-MSCs cultured with PHA-665752
and then exposed to HGF/SF. c-Met inhibitor before HGF/SF incubation revealed almost similar Ki-67 percentage reduced in comparison to
control cells. Scale bars = 50𝜇m. (b)-(c) ∗, ∗∗, ∗∗∗𝑝 value < 0.05, and one-way ANOVA test followed by Bonferroni posttest.
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Figure 3: Migratory effect of HGF/SF on hVW-MSC. (a) Crystal Violet staining of hVW-MSCs migrated into the scratch area after 24 hrs
of exposure to HGF/SF in comparison to the untreated hVW-MSCs; the cell migration was slackened by PHA-665752 before treatment.
Wounded area is delimited by black lines. Scale bars = 50 𝜇m. (b) Quantitative analysis of cell migration area in hVW-MSCs treated with
HGF/SF, in presence and absence of PHA-665752. (c) Immunofluorescence staining for Vimentin revealed that the intermediate filaments
Vimentin (positive (green)) was markedly stained in migrated cells (arrows) then unmigrated cells. Scale bars = 100 𝜇m.The reported images
are representative of three independent experiments.
becomes more evident. At 24 hrs, the number of these struc-
tures significantly decreased, except in samples treated with
HGF/SF. Untreated hVW-MSCs formed very few capillary-
like structures that were completely lost after 24 hrs. Human
Umbilical Vein Endothelial Cells (HUVEC) were used as
positive control and spontaneously formed an extensive
vascular network persisting until 24 hrs (Figure 5(a)). The
number of the capillary-like structures was enhanced in all
experimental conditions in comparison to untreated hVW-
MSCs. Although this increase was statistically significant
in VEGF condition (69 ± 8.4 in VEGF 50 ng/mL versus
14 ± 9.89 in untreated controls, 𝑝 < 0.05; Student’s t-
test), it was more pronounced after HGF/SF stimulation
(Figure 5(b)). As revealed by flow cytometry analysis, the
expression of mature endothelial cell markers, such as vWF,
KDR, and CD31, was clearly promoted by HGF/SF or VEGF
stimulation. In particular, HGF/SF exerted a greater effect
on vWF expression (20% higher compared to VEGF), while
KDR and CD31 were almost similar in the two treatment
conditions (Figure 5(c)). The flow cytometer scores for
each mature endothelial cell marker have been reported in
Figure 5(d). According to the scores, hVW-MSCs precondi-
tionedwithHGF/SF andVEGFunderwent a high endothelial
lineage commitment that was comparable to HUVEC cells.
Conversely, uninduced cells kept their mesenchymal identity.
4. Discussion
Ischemic foot ulcers represent a serious complication of
peripheral arterial disease and the surgical revasculariza-
tion remains the gold standard treatment choice, even if
only 60% of cases reach an effective healing after one-year
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(b)
Figure 4: Motility effect of HGF/SF on hVW-MSCs. Representative Crystal Violet and SEM images of (a) untreated (hVW-MSCs) and (b)
HGF/SF- (10 ng/mL) treated hVW-MSCs migrated through an 8 𝜇m porous membrane adhering to the migration surface. The cell-seeding
surface analysis showed that the chemotactic HGF/SF facilitated the migration of many hVW-MSCs. Histological and SEM images: scale
bars = 50 𝜇m.
treatment [2, 25]. Wound healing is an active and complex
physiological process characterized by a cascade of events
such as homeostasis, inflammation, proliferation, epithelial-
ization, and remodeling; the interplay amongmany cell types,
growth factors, and cytokines regulates each wound healing
steps to achieve a rapidly and complete wound closure [16];
any alteration of these phases may cause an ineffective tissue
repair leading to chronic wounds and their management
requires a very long healing time.
Many strategies have been proposed to accelerate the
wound healing process; among those, proangiogenic gene
and progenitor cell therapy [3, 26], engineered dermis substi-
tute implantation [2, 4], stem cells transplantation [9–11, 27],
topical application of human platelet-derived products [13–
15], and growth factors such as PDGF, VEGF, TGB-beta, FGF,
EGF, and GM-CFS [16, 17] have been developed.
In particular, HGF appears as an interesting multifaceted
protein involved in the entire spectrum of the wound healing
process [28]; HGF has been reported to participate to cell
morphogenesis, motogenesis, mitogenesis, and tissue home-
ostasis, repair, and regeneration through the activation of
its receptor, c-Met. Moreover, HGF is also endowed with
antiapoptotic, anti-inflammatory, and antifibrotic activities
[29] as well as proangiogenesis functions [30, 31].
In our study, we explored the HGF/SF effects on human
stem cells to define a possible mechanism able to improve the
wound healing process. In particular, we chose to investigate
whether HGF/SF could positively influence the multipotent
mesenchymal stem cells that reside within the vascular wall
[24] and that have the potentiality to be mobilized in the
injured tissue to contribute to better and faster wound
healing.
HGF and its c-Met receptor are normally expressed by
epithelial and endothelial cells [32, 33] and bone marrow
mesenchymal stem cells [21–23]; here, we demonstrate that
HGF and its receptor are also expressed in our cell model
both at the mRNA and protein level. In particular, when
hVW-MSCs cultures were exposed to HGF/SF for 24 hrs,
an increase of the c-Met receptor protein levels could be
detected, especially at 10 ng/mL.
The HGF effects on cell proliferation are rather heteroge-
neous and seem to be cell and tissue dependent [21, 30, 34–
36]; few studies reported that HGF/SF inhibits mesenchymal
stem cells proliferation through the cell cycle arrest [22,
37]. In this study, we observed that the administration of
exogenous HGF/SF reduces hVW-MSC proliferation; the cell
proliferation was assayed by using different techniques, that
is, Alamar Blue and immunofluorescence. The proliferative
response was not influenced by long (3 to 7 days) HGF/SF
exposure time, whereas it was significantly increased by short
time (6 hrs) at 10 ng/mL of HGF/SF. At 24 hrs of exposure
time, hVW-MSC proliferation was significantly decreased
using different concentration. Even though a slight reduction
of Ki-67 nuclear expression was seen at 24 hrs of HGF/SF
treatments, parallel experiments performed with the c-Met
antagonist PHA demonstrated that such effect was indepen-
dent of the activation of the HGF/c-MET axis. Substantially,
our results demonstrate that HGF/SF did not exert significant
effects on hVW-MSC proliferation via c-Met receptor.
The migration and the repopulation of the damaged area
is a necessary step to reach the complete healing of wounds.
Among the multiple biological effects of HGF, the motogenic
activity appears to be one of the most powerful activities as
shown in a wide range of several cell types [21, 22, 30, 34].
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Figure 5: Angiogenic effect of HGF/SF on hVW-MSCs. (a) Representative in vitro tube-like formation images of HGF/SF (10 ng/mL for 7
days) and VEGF (50 ng/mL for 7 days) preconditioned hWV-MSCs as well as uninduced hWV-MSCs and HUVEC in Matrigel assay for 2,
6, and 24 hrs from seeding. Scale bars = 100 𝜇m. (b) The quantitative analysis of the capillary-like structures revealed a higher number of
hVW-MSCs exposed to HGF/SF than VEGF-treated cells. ∗𝑝 value < 0.05; Student’s t-test. (c) Flow cytometry analysis of von Willebrand
factor (vWF), KDR, and CD31 expression on untreated hVW-MSCs, HUVEC, and HGF/SF- and VEGF-treated cells. (d) The angiogenic
lineage commitment was evaluated for each treatment attributing a score from 0 to 4 according to flow cytometry values.
The scratch assay is standardized, simple, and inexpensive
approach used to detect this property [38]. Accordingly,
we analyzed the HGF/SF effect on wounded confluent
monolayers of hVW-MSCs, by using several morpholog-
ical approaches including histological staining, SEM,and
immunofluorescence. Our results demonstrated that differ-
ent doses of HGF/SF augmented the hVW-MSC ability to
migrate in the cell-free area restoring the wounded cell
monolayer. Moreover, these migrating cells expressed more
intensely Vimentin, an intermediate filaments marker; this
feature could be related to the cytoskeleton remodeling
phenomenon. The hVW-MSC migration was reduced in
the presence of the c-Met receptor inhibitor, PHA-665752,
even if the HGF/SF addition did not induce the complete
repopulation of the wounded area. As regard the untreated
hVW-MSCs, we saw spontaneous migration, contrary to
literature, probably related to the autocrine secretion of
endogenous HGF released by the same multipotent cells.
The chemoattractive property of HGF/SF was confirmed
through the transwell migration assay. The histological and
ultrastructural observations demonstrated that hVW-MSCs
were able to cross the porous membrane, as attracted by
HGF/SF placed at underlying bottom, and colonize the layer
directly in contact with the growth factor. In the clinical
context, it could be therefore speculated that a steady disposal
of HGF/SF in thewound could recruit endogenous stem cells,
thus promoting tissue repair.
Therapeutic angiogenesis represents another crucial
event in wound healing process. VEGF is a well-established
proangiogenic factor in promoting blood neovessels for-
mation and angiogenesis [39]. In our previous studies [24,
40], VEGF has been demonstrated to be highly effective in
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promoting hVW-MSC endothelial cell lineage commitment.
In that regard, also HGF was proposed as a powerful
angiogenic promoter [30, 31, 41] able to stimulate endothelial
cell proliferation, alignment, and organization into blood
vessel-like structures, although it was originally discovered
as a potent growth factor for liver regeneration [29]. We
assessed the HGF/SF angiogenic potential on our cell model
through an in vitro 3D angiogenesis assay using Matrigel; we
succeeded in demonstrating that HGF/SF pretreated hVW-
MSCs possess a high ability to form an extensive capillary-
like network. Remarkably, the HGF/SF angiogenic effect on
hVW-MSCs was comparable to that seen in the positive
control (HUVEC) and with the VEGF pretreatment; follow-
ing HGF/SF (10 ng/mL) stimulation, the resulting capillary-
like structures persisted even at 24 hrs, suggesting that the
HGF/SF could act on the vascular integrins or adhesion
molecules, therefore stabilizing the endothelial cell junc-
tions. HGF/SF and VEGF growth factors greatly increased
the expression of vWF, KDR, and CD31, typical mature
endothelium markers, supporting an endothelial cell lineage
commitment.
According to our data, the population of vascular mes-
enchymal stem cells basically expresses the HGF and its
receptor, c-Met. Interestingly, the HGF/SF addition was
shown to enhance the hVW-MSC migration and motility
as well as the capillary-like structures formation. These data
suggest that a novel therapeutic strategy, based on the local
delivery of HGF/SF and the involvement of the vascular
wall-MSCs, could be developed to accelerate the healing of
unresponsive vascular ulcers.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper. Sabrina Valente is
partially supported by aGrant fromOctapharmaAG, Lachen,
Switzerland.
Acknowledgment
The authors are grateful to Sabine Noehring from Octa-
pharmaBiopharmaceuticals GmbH, Berlin, Germany, for her
constructive criticism that allowed setting up the experimen-
tal design of the study.
References
[1] N. J. M. London and R. Donnelly, “ABC of arterial and venous
disease. Ulcerated lower limb,” British Medical Journal, vol. 320,
no. 7249, pp. 1589–1591, 2000.
[2] G. Mulder, M. Tenenhaus, and G. F. D’Souza, “Reduction of
diabetic foot ulcer healing times through use of advanced
treatment modalities,” International Journal of Lower Extremity
Wounds, vol. 13, no. 4, pp. 335–346, 2014.
[3] M. Shimamura, H. Nakagami, H. Koriyama, and R. Mor-
ishita, “Gene therapy and cell-based therapies for therapeutic
angiogenesis in peripheral artery disease,” BioMed Research
International, vol. 2013, Article ID 186215, 8 pages, 2013.
[4] T. Lazic and V. Falanga, “Bioengineered skin constructs and
their use in wound healing,” Plastic and Reconstructive Surgery,
vol. 127, pp. 75S–90S, 2011.
[5] H.-J. You, S.-K. Han, J.-W. Lee, and H. Chang, “Treatment of
diabetic foot ulcers using cultured allogeneic keratinocytes—a
pilot study,”Wound Repair and Regeneration, vol. 20, no. 4, pp.
491–499, 2012.
[6] W.A.Marston, J.Hanft, P.Norwood, andR. Pollak, “The efficacy
and safety of Dermagraft in improving the healing of chronic
diabetic foot ulcers: results of a prospective randomized trial,”
Diabetes Care, vol. 26, no. 6, pp. 1701–1705, 2003.
[7] D. S. Kwon, X. Gao, Y. B. Liu et al., “Treatment with bone
marrow-derived stromal cells accelerates wound healing in
diabetic rats,” InternationalWound Journal, vol. 5, no. 3, pp. 453–
463, 2008.
[8] Y. Wu, L. Chen, P. G. Scott, and E. E. Tredget, “Mesenchymal
stem cells enhance wound healing through differentiation and
angiogenesis,” Stem Cells, vol. 25, no. 10, pp. 2648–2659, 2007.
[9] S.-K. Han, H.-R. Kim, and W.-K. Kim, “The treatment of
diabetic foot ulcers with uncultured, processed lipoaspirate
cells: a pilot study,”Wound Repair and Regeneration, vol. 18, no.
4, pp. 342–348, 2010.
[10] C. Nie, D. Yang, J. Xu, Z. Si, X. Jin, and J. Zhang, “Locally
administered Adipose-derived stem cells accelerate wound
healing through differentiation and vasculogenesis,” Cell Trans-
plantation, vol. 20, no. 2, pp. 205–216, 2011.
[11] H. C. Lee, S. G. An, H.W. Lee et al., “Safety and effect of adipose
tissue-derived stem cell implantation in patients with critical
limb ischemia—a pilot study,” Circulation Journal, vol. 76, no.
7, pp. 1750–1760, 2012.
[12] K. M. Lacci and A. Dardik, “Platelet-rich plasma: support for
its use in wound healing,” Yale Journal of Biology and Medicine,
vol. 83, no. 1, pp. 1–9, 2010.
[13] V. R. Driver, J. Hanft, C. P. Fylling, and J. M. Beriou, “A
prospective, randomized, controlled trial of autologous platelet-
rich plasma gel for the treatment of diabetic foot ulcers,”Ostomy
Wound Management, vol. 52, no. 6, pp. 68–74, 2006.
[14] H. S. Setta, A. Elshahat, K. Elsherbiny, K. Massoud, and I.
Safe, “Platelet-rich plasma versus platelet-poor plasma in the
management of chronic diabetic foot ulcers: a comparative
study,” International Wound Journal, vol. 8, no. 3, pp. 307–312,
2011.
[15] T. Slesaczeck, H. Paetzold, T. Nanning et al., “Autologous
derived, platelet-rich plasma gel in the treatment of nonhealing
diabetic foot ulcer: a case report,” Therapeutic Advances in
Endocrinology and Metabolism, vol. 3, no. 2, pp. 75–78, 2012.
[16] S. Enoch, J. E. Grey, and K. G. Harding, “ABC of wound healing.
Recent advances and emerging treatments,” British Medical
Journal, vol. 332, no. 7547, pp. 962–965, 2006.
[17] S. Barrientos, H. Brem, O. Stojadinovic, and M. Tomic-Canic,
“Clinical application of growth factors and cytokines in wound
healing,”WoundRepair andRegeneration, vol. 22, no. 5, pp. 569–
578, 2014.
[18] K. Matsumoto and T. Nakamura, “Emerging multipotent
aspects of hepatocyte growth factor,” Journal of Biochemistry,
vol. 119, no. 4, pp. 591–600, 1996.
[19] K. Okunishi, M. Dohi, K. Nakagome et al., “A novel role of
hepatocyte growth factor as an immune regulator through
suppressing dendritic cell function,” Journal of Immunology, vol.
175, no. 7, pp. 4745–4753, 2005.
Stem Cells International 11
[20] D. P. Bottaro, J. S. Rubin, D. L. Faletto et al., “Identification of the
hepatocyte growth factor receptor as the c-Met proto-oncogene
product,” Science, vol. 251, no. 4995, pp. 802–804, 1991.
[21] S. Neuss, E. Becher, M. Wo¨ltje, L. Tietze, and W. Jahnen-
Dechent, “Functional expression of HGF and HGF receptor/c-
met in adult human mesenchymal stem cells suggests a role in
cell mobilization, tissue repair, and wound healing,” Stem Cells,
vol. 22, no. 3, pp. 405–414, 2004.
[22] G. Forte, M. Minieri, P. Cossa et al., “Hepatocyte growth factor
effects onmesenchymal stem cells: proliferation,migration, and
differentiation,” Stem Cells, vol. 24, no. 1, pp. 23–33, 2006.
[23] K.K.Aenlle, K.M.Curtis, B.A. Roos, andG.A.Howard, “Hepa-
tocyte growth factor andp38 promote osteogenic differentiation
of human mesenchymal stem cells,” Molecular Endocrinology,
vol. 28, no. 5, pp. 722–730, 2014.
[24] S. Valente, F. Alviano, C. Ciavarella et al., “Human cadaver
multipotent stromal/stem cells isolated from arteries stored in
liquid nitrogen for 5 years,” Stem Cell Research & Therapy, vol.
5, no. 1, article 8, 2014.
[25] W. J. Jeffcoate and K. G. Harding, “Diabetic foot ulcers,” The
Lancet, vol. 361, no. 9368, pp. 1545–1551, 2003.
[26] R. Morishita, H. Makino, M. Aoki et al., “Phase I/IIa clinical
trial of therapeutic angiogenesis using hepatocyte growth factor
gene transfer to treat critical limb ischemia,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 31, no. 3, pp. 713–720,
2011.
[27] E. V. Badiavas and V. Falanga, “Treatment of chronic wounds
with bone marrow-derived cells,” Archives of Dermatology, vol.
139, no. 4, pp. 510–516, 2003.
[28] K. Conway, P. Price, K. G. Harding, and W. G. Jiang, “The
molecular and clinical impact of hepatocyte growth factor, its
receptor, activators, and inhibitors in wound healing,” Wound
Repair and Regeneration, vol. 14, no. 1, pp. 2–10, 2006.
[29] T. Nakamura and S. Mizuno, “The discovery of Hepatocyte
Growth Factor (HGF) and its significance for cell biology,
life sciences and clinical medicine,” Proceedings of the Japan
Academy B: Physical and Biological Sciences, vol. 86, no. 6, pp.
588–610, 2010.
[30] F. Bussolino,M. F.DiRenzo,M.Ziche et al., “Hepatocyte growth
factor is a potent angiogenic factor which stimulates endothelial
cell motility and growth,”The Journal of Cell Biology, vol. 119, no.
3, pp. 629–641, 1992.
[31] S.-I. Hayashi, R.Morishita, S. Nakamura et al., “Potential role of
hepatocyte growth factor, a novel angiogenic growth factor, in
peripheral arterial disease: down-regulation ofHGF in response
to hypoxia in vascular cells,”Circulation, vol. 100, supplement 19,
pp. II301–II308, 1999.
[32] M. F. Di Renzo, R. P. Narsimhan, M. Olivero et al., “Expression
of the Met/HGF receptor in normal and neoplastic human
tissues,” Oncogene, vol. 6, no. 11, pp. 1997–2003, 1991.
[33] Y. Nakamura, R. Morishita, J. Higaki et al., “Expression of
local hepatocyte growth factor system in vascular tissues,”
Biochemical and Biophysical Research Communications, vol. 215,
no. 2, pp. 483–488, 1995.
[34] J.-M. Zahm, C. Debordeaux, B. Raby, J.-M. Klossek, N. Bonnet,
and E. Puchelle, “Motogenic effect of recombinant HGF on
airway epithelial cells during the in vitro wound repair of the
respiratory epithelium,” Journal of Cellular Physiology, vol. 185,
no. 3, pp. 447–453, 2000.
[35] R. Ramanujum, Y.-L. Lin, J.-K. Liu, and S. He, “Regulatory
expression of MMP-8/MMP-9 and inhibition of proliferation,
migration and invasion in human lung cancer A549 cells in
the presence of HGF variants,” Kaohsiung Journal of Medical
Sciences, vol. 29, no. 10, pp. 530–539, 2013.
[36] R. Joplin, T. Hishida, H. Tsubouchi et al., “Human intrahepatic
biliary epithelial cells proliferate in vitro in response to human
hepatocyte growth factor,”The Journal of Clinical Investigation,
vol. 90, no. 4, pp. 1284–1289, 1992.
[37] K. Chen, C. Perez-Stable, G. D’Ippolito, P. C. Schiller, B. A.
Roos, and G. A. Howard, “Human bone marrow-derived stem
cell proliferation is inhibited by hepatocyte growth factor via
increasing the cell cycle inhibitors p53, p21 and p27,” Bone, vol.
49, no. 6, pp. 1194–1204, 2011.
[38] C.-C. Liang, A. Y. Park, and J.-L. Guan, “In vitro scratch
assay: a convenient and inexpensive method for analysis of cell
migration in vitro,” Nature Protocols, vol. 2, no. 2, pp. 329–333,
2007.
[39] K. E. Johnson and T. A. Wilgus, “Vascular endothelial growth
factor and angiogenesis in the regulation of cutaneous wound
repair,” Advances in Wound Care, vol. 3, no. 10, pp. 647–661,
2014.
[40] G. Pasquinelli, P. L. Tazzari, C. Vaselli et al., “Thoracic aortas
from multiorgan donors are suitable for obtaining resident
angiogenic mesenchymal stromal cells,” Stem Cells, vol. 25, no.
7, pp. 1627–1634, 2007.
[41] S. Ding, T. Merkulova-Rainon, Z. C. Han, and G. Tobelem,
“HGF receptor up-regulation contributes to the angiogenic phe-
notype of human endothelial cells and promotes angiogenesis in
vitro,” Blood, vol. 101, no. 12, pp. 4816–4822, 2003.
Submit your manuscripts at
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Anatomy 
Research International
Peptides
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation 
http://www.hindawi.com
 International Journal of
Volume 2014
Zoology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Molecular Biology 
International 
Genomics
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Bioinformatics
Advances in
Marine Biology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Signal Transduction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Evolutionary Biology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Biochemistry 
Research International
Archaea
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Genetics 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in
Virolog y
Hindawi Publishing Corporation
http://www.hindawi.com
Nucleic Acids
Journal of
Volume 2014
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Enzyme 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Microbiology
